This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/11/19

    Takeda�s dengue vaccine candidate demonstrates protection in children ages four to 16 years, regardless of previous dengue exposure.

    Takeda Pharmaceutical Company Limited announced that results from the primary endpoint analysis of the ongoing pivotal Phase III Tetravalent Immunization...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/12/22

    EU approves Qdenga vaccine for dengue fever

    Takeda announced that the European Commission (EC) granted marketing authorization for the company’s dengue vaccine Qdenga (Dengue Tetravalent Vaccine) or TAK 003, for the prevention of dengue disease in individuals from four years of age in the European Union (EU)

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    25/07/12

    Sanofi Pasteur Dengue vaccine success in clinical trial

    Sanofi Pasteur, the vaccines division of Sanofi announced that its tetravalent Dengue Vaccine candidate demonstrated proof of efficacy against Dengue,...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    13/09/16

    Takeda initiates TIDES study of TAK 003 vaccine to treat Dengue fever.

    Takeda Pharmaceutical Company Limited announced that it has vaccinated the first subject in the Tetravalent Immunization against Dengue Efficacy Study...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/12/18

    European Commission approves Dengvaxia dengue vaccine.- Sanofi

    The European Commission has granted marketing authorization for Dengvaxia, Sanofi's dengue vaccine. The marketing authorization follows the 18 October 2018,...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    03/09/14

    Final study reports for Dengue fever vaccine- Sanofi Pasteur.

    Sanofi Pasteur, the vaccines division of Sanofi announced that the final landmark phase III efficacy study of its Dengue vaccine...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    28/04/14

    Sanofi Pasteur success in Phase III efficacy study of vaccine for Dengue disease

    Sanofi Pasteur, the vaccines division of Sanofi has announced that the first of two pivotal Phase III efficacy studies with...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    12/11/24

    Potential impact of Takeda’s dengue vaccine candidate (TAK 003) reinforced by long-term safety and efficacy results.- Takeda.

    Takeda Pharmaceutical Company Limited announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual’s previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    11/07/14

    Dengue fever vaccine Phase III results published in The Lancet-Sanofi Pasteur

    Sanofi Pasteur, the vaccines division of Sanofi has announced the publication in The Lancet of the detailed results of its...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/10/18

    CHMP recommends approval of Dengvaxia in dengue disease.- Sanofi.

    The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing...

    See more